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1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause
of cancer death worldwide [1]. HCC is strongly associated with chronic hepatitis B virus (HBV)
or hepatitis C virus (HCV) infection, which are implicated in about 80% of HCCs in certain
geographic area [2]. Risk of HCC is increased 5- to 15-fold in chronic HBV carriers [1] and 11.5-
to 17-fold in HCV-infected patients [3]. In addition, epidemiological studies have shown that
chronic inflammation of the liver predisposes individuals to HCC. Most HCCs are associated
with severe fibrosis or cirrhosis caused by unresolved inflammation. Both HBV and HCV show
a wide spectrum of clinical manifestations, ranging from a healthy carrier state to chronic
hepatitis, cirrhosis and HCC. Notably, HCC occurs less often in chronic viral hepatitis with‐
out cirrhosis. As liver fibrosis progresses from chronic hepatitis to cirrhosis, HCC occurrence
increases [4]. Thus, unresolved inflammation with long-term viral infection leads to HCC
associated with cirrhosis. Approaches to understanding how human HCC develops in chronic
inflammatory liver diseases should therefor focus on molecular mechanisms shared between
liver fibrosis and carcinogenesis (fibro-carcinogenesis).
Transforming growth factor (TGF)-β is a key regulator of many important biologic processes.
TGF-β can inhibit epithelial cell growth, physiologically acting as a tumor suppressor, but it
also can promote neoplasia. TGF-β has been shown to play both tumor-suppressive and tumor
promoting roles [5-7]. As disease progresses toward malignancy, cancer cells gain advantage
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by selective reduction of the tumor-suppressive activity of TGF-β together with augmentation
of TGF-β oncogenic activity [6]. In concert with mitogens, TGF-β induces accumulation of
extracellular matrix (ECM), while mitogenic signaling antagonizes cytostatic TGF-β function
[8,9]. These results indicate that perturbation of TGF-β signaling by mitogens can promote
hepatic fibro-carcinogenesis.
The TGF-β superfamily includes many multifunctional cytokines including TGF-β, activin,
and others [6,10]. Progress over the past 10 years has disclosed important details of how the
TGF-β family elicits its responses [11-14]. Smads, central mediators conveying signals from
receptors for TGF-β superfamily members to the nucleus, are modular proteins with conserved
Mad-homology (MH)1, intermediate linker, and MH2 domains [13]. In cell-signaling path‐
ways, various transcription factors are phosphorylated at multiple sites by upstream kinases.
Catalytically active TGF-β type I receptor (TβRI) phosphorylates COOH-tail serine residues
of receptor-activated Smads (R-Smads), which include Smad2 and the highly similar protein
Smad3 [12]. Mitogenic signals alternatively cause phosphorylation of R-Smad at specific sites
in their middle linker regions [15-20]. After a phosphorylated R-Smad rapidly oligomerizes
with Smad4, this complex translocates to the nucleus, where it regulates transcription of target
genes.
Monitoring phosphorylation status of signaling molecules is a key step in dissecting their
pathways. In Smad signaling, phosphorylation of not only the COOH-tail but also the linker
regions of R-Smads are likely to be important in regulating Smad activity under physiologic
and pathologic conditions [21]. Understanding of molecular mechanisms underlying hepatitis
virus-induced fibro-carcinogenesis can help to guide early management and improve therapy
for patients with chronic liver diseases. This review describes current knowledge of the
molecular pathogenesis of human fibro-carcinogenesis, especially concerning Smad3 phos‐
phorylation profiles. We further consider how enhanced understanding of phospho-Smad3
signaling could lead to more effective prevention of human fibro-carcinogenesis.
2. Smad3 phosphoisoforms
The canonical TGF-β pathway involves Smad2 and Smad3 signaling through direct serine
phosphorylation of COOH termini by TβRI upon TGF-β binding (Figure 1A), [10,13]. TβRI-
mediated phosphorylation of Smad2 and Smad3 induces their association with the shared
partner Smad4, followed by translocation into the nucleus where these complexes activate
transcription of specific genes [10-14]. Smad2 and Smad3 proteins contain a conserved Mad-
homology (MH)1 domain that binds DNA, and a conserved MH2 domain that binds to
receptors, Smad4, and transcription co-activators.
More divergent linker regions separate the two domains [13]. The linker domain undergoes
regulatory phosphorylation by Ras/mitogen-activated protein kinase (MAPK) pathways
including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38
MAPK, and cyclin-dependent kinase (CDK)-2/4, as well as glycogen synthase kinase 3-β, Ca
(2+)-calmodulin-dependent protein kinase II, and G protein-coupled receptor kinase-2 (Figure
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1B), [15-26]. TGF-β alternatively elicits signaling responses through non-Smad pathways
representing important effectors for TGF-β activated kinase (TAK) 1 in response to pro-
inflammatory cytokines. TAK1 activates JNK and p38 MAPK signaling through mitogen-
activated kinase kinase (MKK) 4/7 and MKK3/6 [27,28]. JNK and p38 MAPK have been linked
to modification of TGF-β signaling by pro-inflammatory cytokines through their regulation of
distinct processes such as cytoskeleton organization, cell growth, survival, migration and
invasion [29]. Imbalances between signaling through non-Smad and Smad pathways may
occur during fibro-carcinogenesis, with interaction between these pathways mediating pro-
fibrogenic and pro-tumorigenic effects of TGF-β [30]
Findings in mice with targeted deletion of Smad3 and JNK1 indicate that both Smad3 and
JNK1 pathways promote hepatic fibro-carcinogesis. When acute liver injury was induced by
administration of CCl4, Smad3-/- mice showed approximately half as much of the induction of
collagen type I mRNA as seen in wild-type mice [31]. JNK1-/- mice resisted not only liver fibrosis
 
Figure 1. Reversible phospho-Smad3 signaling between tumor-suppression and fibro-carcinogenesis A) TGF-β
treatment activates TβRI, further leading to direct phosphorylation of Smad3C, which inhibits normally hepatocytic
growth by up-regulating p21WAF1 transcription. B) Mitogens drastically alter phospho-Smad3 signaling via the JNK
pathway, increasing basal nuclear fibro-carcinogenic pSmad3L activity while shutting down TGF-β-dependent cyto‐
static pSmad3C. Although TGF-β signal weakly phosphorylates Smad3L in normal hepatocytes (dotted line), hepatitis
viral components including HBx, pro-inflammatory cytokines including TNF-α, and somatic mutations such as Ras addi‐
tively transmit fibro-carcinogenic signal through the JNK-dependent pSmad3L pathway to participate in hepatocytic
growth and ECM deposition, possibly by stimulating transcription of c-Myc and PAI-1 genes. Linker phosphorylation of
Smad3 indirectly prevents COOH-tail phosphorylation, pSmad3C-mediated p21WAF1 transcriptions and cytostatic func‐
tion. C) Either various JNK inhibitors or a Smad3 mutation causing lack of JNK phosphorylation sites in the linker re‐
gion can eliminate fibro-carcinogenic pSmad3L signaling, restoring or maintaining the tumor-suppressive pSmad3C
signaling characteristic of mature hepatocytes.
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but also HCC development. Remarkable collagen deposition in wild-type and JNK2-/- was less
evident in JNK1-/- mice, suggesting importance of JNK1 in development of liver fibrosis [32].
JNK1-/- mice exhibited impaired liver carcinogenesis with reduced tumor mass, size, and
number [33]. Importantly, JNK1-/- mice displayed decreased HCC proliferation in a carcino‐
genic model and decreased hepatocytic growth in a model of liver regeneration. In both cases,
the impaired proliferation was caused by increased expression of p21WAF1, a cell-cycle inhibitor,
and reduced expression of c-Myc, a negative regulator of p21WAF1.
Mitogens simultaneously activate linker-phosphorylated R-Smad and non-Smad signaling,
with both usually operating in parallel.  Biologic significance of linker-phosphorylated R-
Smad pathways is therefore difficult to assess in isolation. Here we will review recent work
in this area with a particular focus on how mitogens modulate TGF-β signaling through
Smad3 linker phosphorylation, using hepatic fibro-carcinogenesis as an example. Antibod‐
ies (Abs) reactive with structurally related phosphorylated peptides are emerging as valuable
tools for determining phosphorylation sites in vivo and for investigating distinct signals via
phosphorylated domains. Domain-specific phospho-Smad3 Abs have allowed us to reveal
that TβRI and JNK differentially phosphorylate Smad3 to create 2 phosphorylated forms
(phosphoisoforms):  COOH-terminally  phosphorylated  Smad3  (pSmad3C)  and  linker
phosphorylated  Smad3  (pSmad3L)  [34-37].  Linker  phosphorylation  can  modify  COOH-
terminally phosphorylated R-Smad signaling [15-17,19-24]. Differential localization of kinases
and phosphatases in the cytoplasm or nucleus raises the intriguing possibility of differen‐
ces  in  temporal  dynamics  between  cytoplasmic  and  nuclear  R-Smad  phosphoisoforms,
adding  to  the  repertoire  of  signaling  responses  that  determine  cell-fate  decisions  [8,9].
Immunohistochemical and immunofluorescence analyses using specific Abs in human tissues
can examine the clinical significance of context-dependent and cell type-specific signaling
mediated by R-Smad phosphoisoforms by comparison of their tissue and cellular localiza‐
tion in pathologic specimens.
3. Tumor-suppressive (cytostatic) TGF-β signaling: the pSmad3C pathway
TGF-β inhibits proliferation of normal hepatocytes, a crucial function in hepatic homeostasis
[38]. In the context of cell cycle control, the most important targets of action by TGF-β are the
genes encoding two CDK inhibitors (p21WAF1 and p15INK4B) and c-Myc [39]. The pSmad3C signal
induces expression of these CDK inhibitors and represses expression of c-Myc, shutting down
cell cycle progression in the early to mid G1 phase of the cell cycle (Figure 1A). Development
of HCC is ordinarily blocked through actions of the pSmad3C pathway, which causes normal
hepatocytes to cease growth and enter apoptosis after hepatocytic proliferation.
4. Carcinogenic (mitogenic) JNK signaling: the pSmad3L pathway
Mitogens strongly activate the JNK pathway, as TGF-β does more weakly (Figure 1B) [40]. Ras/
MAPK signaling has been shown to induce phosphorylation of Smad2 and Smad3 at their
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linker regions [15]. Smad2 phosphorylation at the linker region inhibits nuclear accumulation
of Smad2 without interfering with TGF-β-induced phosphorylation of its COOH-tail
[19,41-50]. In contrast, linker phosphorylation does not retain Smad3 in the cytoplasm,
permitting further consequences of Ras/JNK signaling. Mechanisms underlying this difference
between the two R-Smads are not known, but phosphorylation sites of Smad3 at clusters of 3
serine residues in its linker region (Ser204, Ser208, and Ser213) somewhat differ in sequence
location from the corresponding linker phosphorylation sites of Smad2 (Ser245, Ser250, and
Ser255).
Several lines of evidence indicate that JNK transmits carcinogenic (mitogenic) signal via the
pSmad3L pathway. First, JNK can directly phosphorylate Smad3 linker sites in vitro, while
JNK inhibitors block Smad3 linker phosphorylation in vivo [16,19]. Second, mitogens translo‐
cate pSmad3L into the nucleus [16,19,20]. Third, nuclear pSmad3L forms a hetero-complex
with Smad4 [16,23]. Fourth, nuclear pSmad3L binds to the Smad-binding element in the
promoter with high affinity and specificity [23,51-53]. Finally, mitogens induce growth of
normal epithelial cells by up-regulating c-Myc, and such mitogenic effects are blocked in
Smad3 mutants lacking linker phosphorylation sites and by JNK inhibitors [19,54]. These
results strongly support the notion that JNK specifically signals via Smad3 [55].
5. Reversible shifts in phospho-Smad3 signaling between tumor-
suppression and carcinogenesis
JNK/pSmad3L and TβRI/pSmad3C signals oppose each other; most importantly, the balance
between carcinogenesis and tumor-suppression can shift (Figure 1C). Linker phosphorylation
of Smad3 blocks COOH-tail phosphorylation induced by TβRI [16,19,24,54,56]. Mitogenic
signaling accelerates nuclear transport of pSmad3L from the cytoplasm, while preventing
Smad3C phosphorylation, pSmad3C-mediated transcription, and anti-proliferative effects of
TGF-β [16,19]. Smad3 mutants lacking linker phosphorylation sites, as well as JNK inhibitors,
can restore growth inhibitory and transcriptional responses to TGF-β in Ras-transformed cells
and pre-neoplastic hepatocytes, both in vitro and in vivo [19,54,56]. Our model implies that the
JNK pathway directly or indirectly modulates pSmad3C- and pSmad3L-mediated signaling
to regulate target genes, resulting in an antagonistic relationship between carcinogenesis and
tumor-suppression. Thus, effectiveness of tumor-suppressive TGF-β signaling can depend on
extent of Smad3 phosphorylation at the linker region.
6. Homeostatic termination of mitogenic JNK/pSmad3L/c-Myc signaling
after liver regeneration by hepatocytic TβRI/pSmad3C/p21WAF1 signaling
Carcinogenesis is currently thought to occur as a sequence of steps termed initiation, promo‐
tion, and progression. Each step is characterized by disruption of normal cellular control
mechanisms. Thus, development of HCC involves sequential alterations of physiological
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mechanisms regulating hepatocytic growth. Before consideration of molecular mechanisms of
hepatocarcinogenesis, examination of the physiologic role of phospho-Smad3 signaling in liver
regeneration is instructive. A unique feature of adult mammalian liver is its ability to accurately
regenerate lost mass, which occurs following surgical resection or diffuse liver injury [57].
Although precise identities of cytokines and molecular mechanisms involved in liver regen‐
eration are largely unknown, TGF-β and tumor necrosis factor (TNF)-α apparently act as
positive and negative regulators of hepatocytic growth, respectively (Figure 1 A and 1B).
Hepatocytes undergo transition from a resting to a proliferative state after acute liver injury
or partial hepatectomy [57]. Loss of parenchyma rapidly induces a wave of hepatocytic
proliferation capable of restoring the total mass of the liver to normal. Several converging lines
of evidence have established that pro-inflammatory cytokines such as TNF-α and interleukin
(IL)-6 are important components of the mitogenic pathways leading to regeneration after acute
liver injury [58]. Treatment of hepatocytes with antibodies against TNF-α resulted in decreased
DNA synthesis and JNK activity [38]. DNA synthesis during liver regeneration was severely
impaired in mice with a TNF-α type I receptor deficiency [59]. After acute liver injury, TGF-
β increases in damaged livers within a time frame similar to that of increases in pro-inflam‐
matory cytokines [60-62]. This raises the problem of how hepatocytes manage to proliferate in
response to a mitogenic pro-inflammatory cytokine signal despite elevated TGF-β concentra‐
tion. During liver regeneration, hepatocytes acquire temporary resistance to cytostatic effect
of TGF-β, allowing them to proliferate [61-63]. The phosphorylation pattern of Smad3 in
regenerative hepatocytes after acute liver injury suggested important participation of phos‐
pho-Smad3 in hepatocytic growth regulation. In actively growing hepatocytes, intracellular
phosphorylation at Smad3L was found to be high [54,56,64]. Translocated to the nucleus,
inflammatory cytokine-induced pSmad3L stimulated c-Myc transcription [54,64,65], which
increased proliferation of hepatocytes and opposed the cytostatic action of the pSmad3C/
p21WAF1 pathway (Figure 1B). Accordingly, pSmad3C/p21WAF1 was undetectable in regenera‐
tive hepatocytic nuclei; escape from TGF-β-induced cytostasis was crucial in a subset of
progenitor cells devoted to ensuring epithelial renewal. Thus, pSmad3L signaling can permit
liver regeneration in response to mitogenic pro-inflammatory cytokines even though TGF-β
concentration is elevated after acute liver injury.
Liver regeneration is tightly controlled by a delicate balance between hepatocytic growth and
inhibition. Anti-mitotic effects of TGF-β contribute to the termination of hepatocyte prolifer‐
ation observed following the wave of DNA synthesis in the regenerating liver. Post regener‐
ation, return of TGF-β sensitivity thus limits hepatocyte proliferation and terminates liver
regeneration [61,63]. After TNF-α and pSmad3L decreased, hepatocytic proliferation ceased,
as decreases in pSmad3L allowed increased sensitivity to phosphorylation at Smad3C by TβRI
(Figure 1C). TGF-β-dependent pSmad3C appears to limit the proliferative response of
regenerating hepatocytes through inhibition of the G1 to S phase transition in the cell-cycle.
Such signaling represents a highly effective defense mechanism against development of HCC,
since nonproliferating hepatocytes containing pSmad3C that might have sustained any
mutations are destined to die [66].
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7. Liver fibrosis as the largest single risk factor for HCC occurrence
Liver fibrosis usually precedes the multistage process of HCC development. Liver fibrosis is
strongly associated with HCC, with 80 to 90% of HCCs arising in cirrhotic livers [67]. In
hepatitis B infection is a risk factor for HCC, along with age, gender, viral DNA load, and viral
core promoter mutation [68]. Fibrosis has also been identified as risk factor in hepatitis C
infection, where cancer risk is directly related to fibrosis severity [69]. Similarly, HCC devel‐
opment is linked to alcoholic cirrhosis [70], nonalcoholic steatohepatitis (NASH) [70], and
hemochromatosis [71], with a yearly HCC incidence of 1.7% in alcoholic cirrhosis [70] and 2.6%
in NASH cirrhosis [72].
8. Involvement of both myofibroblasts and hepatocytes in liver fibrosis
Hepatic fibrosis is characterized by accumulation of excess ECM proteins, regardless of
underlying etiology. Amount of matrix deposition reflects a balance between matrix synthesis
and degradation [73,74]. When synthesis of ECM exceeds degradation, pathologic accumula‐
tion of ECM leads to liver fibrosis. Reversibility of experimental hepatic fibrosis and a striking
decrease in collagenolytic activity observed in liver fibrosis models suggest crucial importance
of impaired matrix degradation in hepatic fibrogenesis [75]. The plasminogen activator/
plasmin system, which is situated upstream of the fibrolysis system, can directly degrade
matrix components, and indirectly inhibit ECM deposition [76]. Plasminogen activator
inhibitor-1 (PAI-1), the major physiologic inhibitor of plasminogen activator, is a potent
promoter of fibrosis. Introduction of a PAI-1 small interfering RNA attenuates deposition of
ECM and hydroxyproline content in experimental hepatic fibrosis [77].
Liver fibrosis is one of the most common pathologic processes occurring in response to
increased inflammatry factors. A complex interplay among different hepatic cell types takes
place in injured livers. Hepatocytes are the targets for most hepatotoxic agents, including
hepatitis viruses, alcohol metabolites, and chemical toxins [78]. Damaged hepatocytes induce
recruitment of white blood cells by local inflammatory cells. Apoptosis of damaged hepato‐
cytes stimulates fibrogenesis by Kupffer cells. Activated Kupffer cells secrete pro-inflamma‐
tory cytokines including TNF-α and IL, as well as TGF-β. Intensive studies have shown that
hepatic stellate cells (HSC) are the major cell type responsible for matrix production in
damaged liver tissues [75]. HSC, characterized by retinoid droplets in the cytoplasm, are
present in the space of Disse [79].
Standardized methods of obtaining HSC from livers have been developed [80]. Long-term
culture of HSC on plastic substrates is widely accepted as a model of liver fibrosis [79]. HSC
spontaneously transdifferentiate to a myofibroblast (MFB) phenotype on plastic dishes, and
this response reproduces the features of activation in vivo. MFB usually retain fibrogenic TGF-
β signaling component, but have lost the capacity to respond to TGF-β with growth arrest [81].
Such a state of altered TGF-β responsiveness is also observed in pre-neoplastic hepatocytes,
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which typically exhibit a limited growth inhibitory response to TGF-β, instead responding to
TGF-β with pro-fibrogenic behavior [9].
Hepatic fibrosis results from a wound-healing response to repeated injury in chronic liver
diseases [82], in which HSC undergo dramatic phenotypic activation, with acquisition of
fibrogenic properties. Patients develop liver fibrosis as a result of chronic liver damage,
characterized by ECM accumulation that distorts hepatic architecture by forming a fibrous
scar [79]. Ultimately, nodules of regenerating hepatocytes become enclosed by scar tissue, an
event defining cirrhosis. Excess deposition of ECM of which type I collagen predominates
disrupts the normal architecture of the liver, resulting in pathologic damage with pathophy‐
siologic consequences.
A new concept has been proposed that epithelial cells undergo a phenotypical change termed
epithelial-mesenchymal transition (EMT), acquiring a fibroblastic phenotype. EMT facilitates
metastasis and cancer development [83]. Pioneering studies on EMT in organ fibrosis were
carried out in kidney, ocular lens, and lung [84,85]. Involvement of EMT also has been
proposed in liver fibrosis. Zeisberg et al. demonstrated that hepatocytes acquire expression of
fibroblast-specific protein 1 in response to CCl4 injury in vivo or TGF-β in vitro [86].
9. Fibrogenic pSmad3L signaling shared between MFB and pre-neoplastic
hepatocytes
As a result of chronic liver damage, HSC undergo progressive activation to become MFB-like
cells. During transdifferentiation in culture, pSmad3C-mediated signal decreases while the
pSmad3L pathway predominates [23]. These observations complement the finding of
pSmad3L rather than pSmad3C in nuclei of α-smooth muscle actin (SMA)-immunoreactive
MFB in portal tracts of chronically HCV-infected liver specimens [64]. The presence of α-SMA
is associated with transdifferentiation of HSC into scar-forming MFB, an event considered
pivotal in the fibrogenic response [75].
Plasma TGF-β, TNF-α, and PAI-1 concentrations are usually elevated in patients with chronic
liver diseases [87-89]. Since pSmad3L can transmit a fibrogenic signal by stimulating PAI-1
transcription (Figure 1B) [23], we investigated the pSmad3L pathway in human chronic liver
disease. The results indicated nuclear localization of pSmad3L in PAI-1-immunoreactive MFBs
and hepatocytes in chronic hepatitis specimens [64]. Thus, hepatocytes are regulated by the
same pSmad3L pathway as are MFBs. Hepatocytes in HCV-infected livers, particularly those
adjacent to inflamed portal tracts, exhibited phosphorylation at Smad3L [64]. Extent of
phosphorylation at Smad3L was less in hepatocytes distant from portal tracts, in sharp contrast
to pSmad3C, which was predominantly located in hepatocytic nuclei distant from portal tracts
[64]. Extent of hepatocytic pSmad3L/PAI-1 increased in proportion to fibrotic stage in chronic
liver diseases [56,74]. TGF-β and pro-inflammatory cytokines are released from infiltrating
Kupffer cells in portal tracts to activate JNK [90,91]. Considering these findings together with
a previous observation showing transcriptional activation of the PAI-1 gene by JNK [92], TGF-
β and TNF-α can mediate JNK/pSmad3L signaling that in turn induces PAI-1 expression and
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promotes ECM deposition in both hepatocytes and MFB. Thus, hepatocytes affected by chronic
inflammation undergo transition from the tumor-suppressive pSmad3C pathway, character‐
istic of mature hepatocytes, to the JNK/pSmad3L/PAI-1 pathway, which favors a state of flux
characterized by MFB.
Our findings support many important papers reporting that hepatocytes can promote
fibrogenesis via TGF-β/Smad signaling. Dooley et al. reported that overexpression of inhibi‐
tory Smad7 in hepatocytes attenuated TGF-β-mediated fibrogenesis by blocking Smad
signaling [93]. Since the large latent TGF-β complex consisting of TGF-β, the N-terminal part
of its precursor, and the latent TGF-β binding protein exists in not only HSC but also hepato‐
cytes, the complex can transmit a pro-fibrogenic signal [94], although intracellular functions
of the TGF-β complex are poorly understood. TGF-β down-stream mediator connective tissue
growth factor (CTGF) also involves hepatic fibro-carcinogenesis [95]. CTGF expression
increases in fibrotic livers and various tumor tissues [96]. More importantly, in vivo knockdown
of CTGF by small interfering RNA leads to substantial attenuation of experimental liver
fibrosis. Differential regulation of CTGF expression in hepatocytes and HSC by Smad2
signaling may contribute to hepatic fibro-carcinogenesis [97]. Interestingly, a methylxanthine,
caffeine, inhibits synthesis of CTGF in hepatocytes and HSC, primarily by inducing degrada‐
tion of Smad2 [96].
10. Additive promotion of human carcinogenesis by persistent hepatitis
viral infection and chronic inflammation
Various experiments support the notion that a single promoting agent is insufficient for
development of cancer. Hepatocarcinogenesis is multi-factorial, involving collaboration
between 2 or more promoting agents in HCC occurrence [98]. Among tumor-promoting
agents, hepatitis viruses and chronic inflammation directly participate in HCC pathogenesis,
which frequently occurs during long-standing hepatitis viral infection.
Many clinical observations suggest that persistent hepatitis viral infection and chronic
inflammation additively influence development of human HCC. For example, alcohol
consumption is a recognized major cause of liver disease, and plays an important role in
progression to HCC. However, alcoholic hepatitis progresses less frequently to HCC than
HBV- or HCV- related hepatitis. In addition, patients with both viral infection and alcohol
consumption have a higher risk of developing HCC than those with alcohol consumption alone
[3,99,100]. Autoimmune hepatitis (AIH) and primary billiary cirrhosis (PBC) are chronic
inflammatory disorders that proceed to cirrhosis. However, HCC only rarely arises from AIH
or PBC, particularly in the absence of HBV or HCV infection [101,102]. Conversely, asympto‐
matic HBV or HCV carriers maintaining normal alanine aminotransferase (ALT) levels despite
intensive viral replication less frequently develop HCC than patients with chronic hepatitis B.
The annual risk of HCC occurrence in HBV healthy carriers is 0.26% to 0.6%, while risk
increases to 1% in patients with chronic active hepatitis B [103]. Moreover, HBV can act
synergistically with HCV. Patients co-infected with HBV and HCV have a 2- to 6-fold higher
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risk of HCC occurrence than those with either infection alone [104,105]. Accordingly, we will
consider how the oncogenic JNK/pSmad3L pathway induces development of HCC, with
particular attention to potential synergy between hepatitis viruses and inflammation in
formation of pre-neoplastic hepatocytes.
11. Hepatitis virus components can activate oncogenic JNK/pSmad3L
pathway
One of the earliest evidence linking HBV to development of HCC was obtained in the wood‐
chuck hepatitis virus model, in which 100% of rodents infected with woodchuck hepatitis virus
developed HCC [106]. Because HBV contains partially double stranded-DNA, it can directly
cause HCC by integrating its DNA into the host genome. HBV genomic integration is present
in over 85% to 90% of HBV-related HCC, usually even before development of HCC [107].
Integration of HBV DNA is not restricted to HCC but also is found in non-tumor tissue in
patients with chronically HBV infection [108,109]. HBV integration induces a wide range of
genetic alterations within the host genome, including chromosomal deletions, translocations,
production of fusion transcripts, amplification of cellular DNA, and generalized genomic
instability [110,111]. Many integration events occur near or within fragile sites or other cancer-
associated regions of the human genome that are prone to instability in tumor development
and progression. Genetic instability associated with integration may alter expression of
oncogenes, tumor suppressor genes, and microRNAs [111]. A recent large-scale analysis of
HBV DNA integration sites in cellular DNA found a preference for sites regulating cell
signaling, proliferation, and viability [112]. A large proportion of HCC have integrated HBV
sequences encoding HBV X (HBx) and/or truncated envelope pre-S2/S proteins.
The HBx protein encoded by the X gene has been long suspected as a viral oncoprotein
participating in hepatocarcinogenesis. This protein is involved in liver cell transformation
because of its pleiotropic activities on cell cycle regulation, cell signaling pathways and DNA
repair [113-115]. Numerous attempts have been made to examine the oncogenic potential of
HBx in cell culture. However, its transforming ability was barely measurable evident only
when cells were immortalized by other oncogenes, such as SV40 T-antigen [116,117] or TGF-
α [118]. Furthermore, most transgenic mice harboring the HBx gene did not develop serious
liver diseases or tumors [119]. Only in a certain transgenic lineage of CD-1 strain, HBx weakly
promoted carcinogenesis, where HBx was highly expressed [120]. A second mouse lineage
with lower HBx expression developed liver tumors at the same rate as normal CD-1 mice [121].
HBx was shown to potentiate c-Myc-induced liver carcinogenesis in transgenic mice [122].
Thus, HBx does not have strong transforming activity, but HBx overexpression in a certain
genetic background might induce tumor formation in a multistage transformation, most likely
in collaboration with other cellular oncogenic pathways.
HBx is mainly located in the cytoplasm and exhibits pleiotropic effects that modulate cell
responses to oncogenic signaling pathways [114]. HBx protein do not bind directly to DNA,
but rather acts on cellular promoters. Such protein-protein interaction can modulate cytoplas‐
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mic pathways [113,114,123]. For example, HBx protein was found to activate the JNK-
dependent pathway and up-regulate oncogenic c-Myc gene expression [124].
To investigate whether HBx alters phospho-Smad3 signaling in hepatocytes, we stably
transfected immortalized rat hepatocytes using a construct of HBx with a mammalian
expression vector, resulting in high HBx-expressing cells [56]. High expression of HBx protein
in hepatocytes tended to shut down pSmad3C-mediated signaling and favored acquisition of
constitutively active JNK-mediated pSmad3L signaling, which fostered hepatocytic growth
by up-regulating c-Myc (Figure 1B).
In transgenic models, HBx played an important role in hepatocarcinogenesis via the pSmad3L/
c-Myc pathway [56]. HBx transgenic mouse livers progressed through hyperplasia to HCC.
HBx, pSmad3L, and c-Myc were not detected in normal mouse livers. Beginning at the age of
2 months, HBx transgenic mouse liver showed centrilobular foci of cellular alteration with
cytoplasmic vacuolation surrounding central veins where Bromodeoxyuridine (BrdU) was
uptaken into the hepatocytes [121]. Smad3L was phosphorylated in hepatocytic nuclei of the
centrilobular region, where HBx and c-Myc were expressed. Hepatocytic HBx, pSmad3L, and
c-Myc increased as mouse liver progressed through hyperplasia to HCC.
Positivity of hepatocytic nuclei for pSmad3L in early chronic hepatitis B specimens increases
with amount of HBV-DNA [56]. Taken together with results of in vitro experiments using HBx-
expressing hepatocytes and HBx transgenic livers, these human findings indicate that HBx
oncoprotein participates directly in hepatocarcinogenesis by shifting hepatocytic phospho-
Smad3 signaling from the tumor-suppressive pSmad3C/p21WAF1 pathway to the oncogenic
JNK/pSmad3L/c-Myc pathway (Figure 1B), [56].
Unlike HBV, HCV is a positive-single-strand RNA virus, apparently incapable of integration
into the host's genome. The HCV genome has a long open reading frame, which encodes a
polyprotein precursor [125,126]. This polyprotein is cleaved by both host and viral proteases
to generate 4 structural proteins (C, E1, E2, and P7) and 6 nonstructural proteins (xlink, NS3,
NS4A, NS4B, NS5A, and NS5B) [127,128]. The HCV components modulate a number of cellular
regulatory functions by targeting a wide spectrum of cellular signaling pathways [129-136].
HCV core expression has been shown to induce activation of the JNK pathway in regulation
of vascular endothelial growth factor [136]. NS5A acts as a positive regulator of the JNK
signaling pathway by interacting with tumor necrosis factor receptor-associated factor 2,
which may play a key role in HCV pathogenesis [137]. In an HCV infection model, Lin et al.
demonstrated that HCV directly induced TGF-β release from hepatocytes in reactive oxygen
species (ROS)-dependent and JNK-dependent manner [138]. Moreover, recent studies using
transgenic mouse models indicate that HCV directly involves hepatocarcinogenesis. Three
different HCV core transgenic lines develop liver steatosis and HCC [139-141]. Accordingly,
future studies are expected to prove that the HCV components can activate the oncogenic JNK/
pSmad3L pathway.
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12. Activation of the oncogenic JNK/pSmad3L pathway by chronic
inflammation
Inflammatory microenvironments are present in human hepatocarcinogenesis before malig‐
nant change occurs. A hepatitis virus infection triggers chronic inflammation, increasing the
risk of HCC development. Several studies have discussed how chronic inflammation affects
the proliferation and survival of hepatocytes [142,143]. TNF-α, IL-1β and IL-6 are multifunc‐
tional pro-inflammatory cytokines largely responsible for the hepatic response to chronic
inflammation [144-146]. Serum concentrations of these cytokines are increased in chronic liver
inflammation including hepatitis viral infection and steatohepatitis [147]. JNK is a key signal
transducer for inflammatory cytokines and has emerged as an important endogenous tumor
promoter [148,149].
TGF-β is also released by infiltrating Kupffer cells, the liver's resident macrophages, in portal
tracts during chronic inflammation [150]. These findings suggest that elevated pro-inflamma‐
tory cytokines might alter hepatocytic TGF-β signaling in inflammatory microenvironments.
We investigated this hypothesis using rat cultured hepatocytes [64]. Pretreatment of hepato‐
cytes with SP600125, a JNK inhibitor, reduced the subsequent increase in pSmad3L, c-Myc
transcription, and hepatocytic growth triggered by pro-inflammatory cytokine stimulation
(Figure 1C), suggesting a direct role of the JNK/pSmad3L/c-Myc pathway in facilitating
hepatocytic growth in response to cytokine stimulation (Figure 1B).
Experimental models of HCC including inflammation can elucidate how chronic inflammation
contributes to hepatocarcinogenesis. In a rat model involving diethylnitrosamine (DEN)-
induced carcinogenesis, chronic inflammation liver accompanies abnormalities that progress
to HCC [151]. This DEN-induced rat HCC is histologically and genetically similar to human
HCC, and also is associated with chronic inflammation [152]. In this chemical model, JNK act
participates importantly in hepatocarcinogenesis via pSmad3L/c-Myc signaling. In DEN-
treated livers, the JNK/pSmad3L/c-Myc pathway was activated in early pre-neoplastic
hepatocytes (Figure 1B), [54]. Moreover, a JNK inhibitor SP600125 suppressed HCC develop‐
ment in DEN-treated rat livers by restoring carcinogenic pSmad3L/c-Myc to the basal
pSmad3C/p21WAF1 pathway in the pre-neoplastic hepatocytes (Figure 1C), [54].
In human chronic hepatitis C specimens, mainly in groups of hepatocytes adjoining inflam‐
matory cells in portal tracts, Smad3 was found to be phosphorylated at the linker region [64].
Furthermore, positivity of hepatocytic nuclei for pSmad3L/c-Myc in chronic hepatitis C
specimens showed a significant relationship with necrosis and inflammatory activity [64].
Taken together with the results of in vitro experiments and DEN-treated rat livers, the human
findings indicate that chronic inflammation directly participates in hepatocarcinogenesis by
shifting hepatocytic phospho-Smad3 signaling from the tumor-suppressive pSmad3C/
p21WAF1 pathway to the oncogenic JNK/pSmad3L/c-Myc pathway [54,64].
Many tumor-enhancing effects of pro-inflammatory cytokines on hepatocytes are exerted at
the level of tumor promotion [58]. TNF-α promotes HCC occurrence in mice lacking the P-
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glycoprotein Mdr2 [153]. HCC follows cholestatic inflammation in these mice. Incidence of
HCC can be enhanced by another member of the TNF family, lymphotoxin β [154]. Tumor-
promoting cytokines produced by Kupffer cells activate several transcription factors, includ‐
ing NF-kB, STAT3, and AP-1, in pre-malignant hepatocytes [155]. The activated transcription
factors stimulate transcription of their target genes involved in hepatocytic proliferation and
survival, representing a major tumor-promoting mechanism. Similarly to these transcription
factors, tumor-promoting actions of hepatocytic Smad3 in human chronic liver disease rarely
result from direct mutations [156]. Instead, pSmad3L depends on mitogenic pro-inflammatory
cytokine signals produced by neighboring Kupffer cells.
13. Constitutive phosphorylation at Smad3L in pre-neoplastic hepatocytes
in cirrhotic human liver
The mechanism regulating regeneration, which avoids accumulation of deleterious mutations
in genes that promote cell growth and division, must be disrupted before hepatocytes can
throw off normal restraints and behave as an asocial HCC. Constitutive phosphorylation at
Smad3L is observed in pre-malignant hepatocytes in cirrhosis [56,64]. Constitutively active
pSmad3L stimulates hepatocytes to proliferate continuously in human livers that normally
experience little proliferation because hepatocytic regeneration is tightly regulated by cyto‐
static pSmad3C signaling. Since JNK is constitutively activated in pre-neoplastic hepatocytes
in cirrhotic human liver [157], constitutive Smad3L phosphorylation in pre-malignant lesions
can be a direct consequence of proto-oncogene-mediated JNK signaling. Somatic mutations in
pre-neoplastic hepatocytes include changes in the Ras pathway that favor progression from
cirrhosis toward HCC [158]. In pre-neoplastic hepatocyte nuclei, pSmad3L/c-Myc can accu‐
mulate when somatic mutations constitutively activate the JNK pathway to phosphorylate
Smad3 at the linker region (Figure 1B). Then, the proliferative effect mediated via the pSmad3L/
c-Myc pathway constitutively keeps on suppresses the growth-inhibitory pSmad3C/p21WAF1
pathway in the nuclei of pre-neoplastic hepatocytes.
Pre-neoplastic hepatocytes and HCC show reduction of anti-mitogenic responses to TGF-β
[20,37]. Escaping the cytostatic action of pSmad3C is a critical step for progression to full
malignancy in cancers, which must overcome multiple fail-safe genetic controls [39,159,160].
The TGF-β/pSmad3C pathway is required for maintenance of genomic stability, induction of
replicative senescence, and suppression of telomerase [161-163]. Selection for genetic instabil‐
ity occurs in clones of aberrant cells able to produce tumors, since genetic instability greatly
accelerates accumulation of further genetic and epigenetic changes required for tumor
progression. In this regard, the TGF-β/pSmad3C pathway contributes to tumor suppression
along with its cytostatic effect.
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14. Chronic inflammation together with hepatitis virus effects in shifting
phospho-Smad3 signaling into oncogene-dependent fibro-carcinogenic
signaling
In the pathogenesis of HCC, continuous viral infection and chronic inflammation have a
prominent role. On the other hand, detailed analysis of HCC development in experimental
animals and correlation of these results with HCC in humans has identified a variety of
genomic and molecular alterations in fully developed HCC [164]and to a lesser extent in
morphologically defined pre-neoplastic precursor lesions [165]. Thus, a series of mutations
may accumulate in individual hepatocytes over time. Finally, hepatocytes come to carry
somatic mutations that lead to focal uncontrolled hepatocytic growth and eventual malignant
cell transformation, in some cases, HCC [166].
Chronic inflammation associated with hepatitis virus infection may be the primary initial
requirement in multistep hepatocarcinogenesis. If pSmad3L-positive and pSmad3C-negative
hepatocytes survive in the course of chronic hepatitis, such hepatocytes and their descendants
can accumulate, and acquire various mutated alleles. Mutations may involve genes in Ras
pathway [158]that impel pre-neoplastic hepatocytes with constitutive phosphorylation at
Smad3L toward a neoplastic growth [8]. Tumor promotion results in further selective clonal
expansion of initiated cells, thereby enhancing the likelihood of additional genetic damage as
a consequence of endogenous mutations. During tumor progression, premalignant cells
continue to develop progressive phenotypic changes and genomic instability, developing into
overt HCC.
15. The JNK/pSmad3L pathway as a therapeutic target to avert HCC
development
Clinical analyses of pSmad3L and pSmad3C in human tumor formation have provided
substantial mechanistic insights. For example, specimens from patients with chronic hepatitis
B who develop HCC show abundant Smad3L but limited Smad3C phosphorylation in
hepatocytic nuclei, while other patients with abundant hepatocytic pSmad3C but limited
pSmad3L do not develop HCC [56]. The same relationships are observed in human HCV-
related hepatocarcinogenesis [64]. These clinical observations support roles for pSmad3C as a
tumor-suppressor and pSmad3L as a promoter during human carcinogenesis.
HCC is a highly chemoresistant cancer with no effective systemic cytotoxic chemotherapy
[167]. Despite surgical or locoregional therapies, the prognosis remains poor because of high
likelihood of tumor recurrence or progression and there are no well-established effective
adjuvant therapies [168]. Molecular events that affect carcinogenesis need to be identified and
targeted to validate new treatment approaches and expand available therapeutics to include
chemoprevention to other therapeutics. Since JNK acts as an important regulator of Smad3
signaling that increases the basal amount of hepatocytic pSmad3L available for cell growth
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while inactivating the TGF-β-dependent cytostatic actions of pSmad3C (Figure 1B), pharma‐
cologic interference with JNK/pSmad3L signaling could interrupt carcinogenesis. A key
therapeutic aim in chronic liver disorders is restoration of lost tumor-suppressive function
observed in normal hepatocytes, at the expense of effects promoting hepatic carcinogenesis
[169]. To accomplish this difficult aim, Nagata et al. (2009) administered a JNK inhibitor
SP600125 to rats and were able to suppress chemical carcinogenesis by shifting hepatocytic
Smad3 signaling from the carcinogenic pSmad3L pathway to the tumor-suppressive pSmad3C
pathway (Figure 1C), [54]. These studies provide evidence that JNK/pSmad3L is an important
target for development of chemopreventive and therapeutic measures to reduce emergence of
HCC in the context of chronic liver injury and to slow progression of existing tumors. We must
also consider whether long-term use of any drug inhibiting C-terminal phosphorylation of R-
Smads might cause cancer development [7].
 
 
Figure 2. After hepatitis virus infection, early chronic inflammation and subsequent somatic mutations shift
hepatocytic phospho-Smad3 signaling from the tumor-suppressive TβRI/pSmad3C made to the fibro-carcino‐
genic JNK/pSmad3L mode characteristic of MFB, accelerating liver fibrosis while increasing risk of HCC. Both
hepatitis virus infection and chronic inflammation represent early fibro-carcinogenic steps representing non-mutagenic
tumor-promoting stimuli. In advanced liver fibrosis, mitogenic genetic or epigenetic alterations can drive multistep fibro-
carcinogenesis via the pSmad3L pathway. Escaping the cytostatic action of pSmad3C is a critical step for progression to
full malignancy in cancers, which must overcome multiple fail-safe genetic controls.
16. Conclusion and perspectives
Human fibro-carcinogenesis is a complex multistep process, which involves dysregulation
of physiological signal transduction pathways. To maintain hepatic homeostasis, hepatocyt‐
ic TβRI/pSmad3C/p21WAF1  terminates mitogenic JNK/pSmad3L/c-Myc signaling after liver
regeneration. During progression of chronic liver diseases, however, early pro-inflammato‐
ry  cytokines  together  with  hepatitis  viruses  and  subsequent  somatic  mutations  switch
hepatocytic phospho-Smad3 signaling from the tumor-suppressive TβRI/pSmad3C to the
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fibro-carcinogenic JNK/pSmad3L mode characteristic of MFB, which accelerates liver fibrosis
while increasing risk of HCC (Figure 2). Our model is likely to represent a crucial molecu‐
lar mechanism by which most HCCs arise in from fibrosis or cirrhosis caused by chronic
inflammation associated with persistent hepatitis virus infection [164]. Thus, Smad phosphoi‐
soforms function as an important orchestrator of a human chronic inflammation-fibrosis-
HCC axis [9,170].
Recent studies in animal models using conditional transgenic expression have suggested an
intriguing reversibility of malignant transformation at specific time points if the primary
inciting cause of the neoplasia is eliminated [171,172]. However, the fibro-carcinogenic stage
in human chronic liver at which the process becomes irreversible. Chronic hepatitis B and C
can be cured if patients are treated with antiviral therapy that arrests chronic inflammation by
eradicating hepatic HBV and HCV populations. Continued histologic improvement and
reversal of fibrosis by antiviral therapy can lead to reduction of HCC development [173,174],
but prevention appears most effective when therapy is given before development of cirrhosis.
Chronic hepatitis is clearly dependent on continued promoter stimulation - involving in this
case the presence of hepatitis viruses and chronic inflammation. However, many patients with
cirrhosis have evolved beyond dependence on inflammation because hepatocytes have
acquired genetic and epigenetic carcinogenic properties. We are carrying out several trials to
determine whether or not antiviral therapy can decrease liver fibrosis and lower HCC
incidence. The trials will bear upon important questions regarding relative participation in
fibro-carcinogenesis of inflammation-dependent and oncogene-dependent Smad3 phosphoi‐
soform signaling in HBV- and HCV-related chronic liver disorders. In the trials, pathologic
analyses using domain-specific phospho-Smad3 Abs, together with clinical data, will be used
to evaluate the benefit from antiviral therapy, which decreases stimulation of the inflamma‐
tion-dependent Smad phosphorisoform pathway. After antiviral therapy, hepatocytic
pSmad3L and pSmad3C assessment in liver specimens should prove clinically useful for
predicting progression of fibrosis and risk of HCC.
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